SELLAS Life Sciences Group Inc. (NASDAQ:SLS) has a beta of 1.65. The stock’s Relative Strength Index (RSI) is 79.75, with weekly volatility at 11.25% and ATR at 0.86. The SLS stock’s 52-week price range has touched low of $1.76 and a $19.38 high. Its shares traded lower over the last trading session, losing -1.64% on 06/02/21. The shares fell to a low of $11.25 before closing at $12.60. Intraday shares traded counted 1.15 million, which was -103.9% lower than its 30-day average trading volume of 565.01K. SLS’s previous close was $12.81 while the outstanding shares total 15.08M.
Investors have identified the Biotechnology company SELLAS Life Sciences Group Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $170.35 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
SELLAS Life Sciences Group Inc. (SLS) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 31.43 million total, with 5.97 million as their total liabilities.
Potential earnings growth for SELLAS Life Sciences Group Inc. (SLS)
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 100000.0 trying to sell their products during the last quarter, with the result yielding a gross income of 5.6 million. This allows shareholders to hold on to 15.08M with the recently reported earning now reading -0.16 cents per share. This is a figure that compared to analyst’s prediction for their 08/19/2021 (-0.13 cents a share).
Is the stock of SLS attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 1.00%.
1 out of 1 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on SELLAS Life Sciences Group Inc.. 0 analysts has assigned a Sell rating on the SLS stock. The 12-month mean consensus price target for the company’s shares has been set at $10.00.